Normal Postprandial Nonesterified Fatty Acid Uptake in Muscles Despite Increased Circulating Fatty Acids in Type 2 Diabetes

Sébastien M. Labbé,1 Etienne Croteau,2 Thomas Grenier-Larouche,1 Frédérique Frisch,1 René Ouellet,2 Réjean Langlois,2 Brigitte Guérin,2 Eric E. Turcotte,2 and André C. Carpentier1

OBJECTIVE—Postprandial plasma nonesterified fatty acid (NEFA) appearance is increased in type 2 diabetes. Our objective was to determine whether skeletal muscle uptake of plasma NEFA is abnormal during the postprandial state in type 2 diabetes.

RESEARCH DESIGN AND METHODS—Thigh muscle blood flow and oxidative metabolism indexes and NEFA uptake were determined using positron emission tomography coupled with computed tomography (PET/CT) with [11C]acetate and 14(R,S)-[18F]fluoro-6-thia-heptadecanoic acid ([18F]THA) in seven healthy control subjects (CON) and seven subjects with type 2 diabetes during continuous oral intake of a liquid meal to achieve steady postprandial NEFA levels with insulin infusion to maintain similar plasma glucose levels in both groups.

RESULTS—In the postprandial state, plasma NEFA level was higher in type 2 diabetic subjects versus CON (P < 0.01), whereas plasma glucose was at the same level in both groups. Muscle NEFA fractional extraction and blood flow index levels were 56% (P < 0.05) and 24% (P = 0.27) lower in type 2 diabetes, respectively. However, muscle NEFA uptake was similar to that of CON (quadriceps femoris [QF] 1.47 ± 0.23 vs. 1.37 ± 0.24 mmol · g−1 · min−1, P = 0.77; biceps femoris [BF] 1.54 ± 0.26 vs. 1.46 ± 0.28 mmol · g−1 · min−1, P = 0.85). Muscle oxidative metabolism was similar in both groups. Muscle NEFA fractional extraction and blood flow index were strongly and positively correlated (r = 0.79, P < 0.005).

CONCLUSIONS—Postprandial muscle NEFA uptake is normal despite elevated systemic NEFA levels and acute normalization of plasma glucose in type 2 diabetes. Lower postprandial muscle blood flow with resulting reduction in muscle NEFA fractional extraction may explain this phenomenon. Diabetes 60:408–415, 2011

I

creased intramyocellular triglyceride (IMTG) level correlates with impaired insulin sensitivity in obese insulin-resistant subjects and subjects with type 2 diabetes (1). Experimental elevation of plasma nonesterified fatty acid (NEFA) in humans using intravenous lipid infusion was associated with rapid deposition of IMTG associated with the development of insulin resistance within 4 h (2). Similarly, high-fat diet for 3 days in healthy volunteers induced IMTG accumulation associated with impaired insulin sensitivity (3). It has been demonstrated that subjects with type 2 diabetes have increased postprandial IMTG deposition (4), but the mechanisms leading to this phenomenon have not been elucidated. Impaired muscle fatty acid oxidation has been shown during fasting and during exercise in obese insulin-resistant subjects and subjects with type 2 diabetes (5–7). However, impaired muscle NEFA oxidation was associated with impaired NEFA uptake in the later studies, and suppression of muscle fatty acid oxidation by insulin was reduced in insulin-resistant individuals (5). During similar intravenous fat load, NEFA levels were higher in subjects with impaired glucose tolerance, a phenomenon that is significantly correlated with lipid-induced insulin resistance and impaired β-cell function in vivo (8). We demonstrated that this “impaired NEFA tolerance” during intravenous fat load is associated with increased whole-body palmitate oxidation in offspring of parents with type 2 diabetes (9). Recently, we showed that subjects with type 2 diabetes have increased postprandial NEFA appearance and whole-body oxidation rates without or with acute correction of hyperglycemia using intravenous insulin infusion to clamp glucose level (10).

The aim of the current study was to determine whether postprandial NEFA uptake in thigh skeletal muscles is increased in men with established but well-controlled type 2 diabetes compared with healthy men without a family history of type 2 diabetes. Our hypothesis was that increased postprandial NEFA appearance is associated with increased NEFA uptake in thigh skeletal muscle of men with type 2 diabetes. Our study design also allowed us, as a secondary objective, to determine postprandial leg subcutaneous adipose tissue NEFA uptake that may be a potential mechanism for increased postprandial plasma NEFA levels in type 2 diabetes.

RESEARCH DESIGN AND METHODS

Ethics statement. Informed written consent was obtained from all participants in accordance with the Declaration of Helsinki, and the protocol received approval from the Human Ethics Committee of the Centre Hospitalier Université de Sherbrooke.

Subjects. Seven healthy men without glucose intolerance (controls subjects [CON]), based on a 75-g oral glucose tolerance test, and seven men with established type 2 diabetes aged between 18 and 60 years participated in this metabolic study (Table 1). None of the participants had a current medical condition known to affect lipid levels or insulin sensitivity (other than type 2 diabetes), and participants had no known cardiovascular disease. Type 2 diabetic subjects were well controlled (AIC <7.5%) on diet alone and/or with only one oral hypoglycemic agent (sulfonylurea or metformin). Oral hypoglycemic and antihypertensive drugs, when taken, were stopped for 2 days before the study. Capillary blood glucose and blood pressure were monitored four times a day and daily, respectively, during this period. Statin therapy,
Data are means ± SEM. *From the unpaired Student t test.

when present, was stopped for 3 weeks before the study. None of the participants were taking thiazolidinediones, fibrates, or β-blockers.

**Experimental protocols.** Subjects were instructed to follow an isocaloric diet (60% alcohol, 15% protein, 30% fat, and 55% carbohydrates) 48 h before the experimental protocol. On arrival, body weight, height, and waist circumference were measured, and blood pressure was determined by electrical bioimpedance (Hydra ECF/FIC, Xitron Technologies, San Diego, CA). An intravenous catheter was placed in one forearm for infusions, and another was placed in a retrograde fashion in the contralateral wrist vein maintained in a heating pad (~35°C) for blood sampling.

The metabolic protocol consisted in a steady-state postprandial condition with a glucose clamp using exogenous insulin infusion, as described previously (10) (Fig. 1). Continuous oral intake of a standard liquid meal was designed to achieve steady-state postprandial NEFA and triglyceride (TG) levels over 6 h. The fat drink was prepared by sonication of soybean oil (54 g/L), safflower oil (54 g/L), dried nonfat milk (263 g/L), egg phospholipids (0.18 g/L), and water with the addition of chocolate syrup (202 g/L) and sugar (15 g/L) to provide 2,465 kcal/L (39% as fat, 16% as proteins, and 45% as carbohydrates). The drink's fatty acid composition was similar to the composition of Intralipid, an intravenous fat emulsion that we used in previous studies. The oral intake of the drink corresponded to 28.4 mL every 15 min for a total of 1,680 kcal (74 g fat and 163 g carbohydrates) over 6 h. During the experimental protocol, plasma glucose was clamped at ~5.5–6.0 mmol/L over the last 3 h of the 6-h postprandial period using a variable dextrose 20% (D20%) intravenous infusion adjusted every 5 min, according to plasma glucose level (Beckman Glucose Analyzer II; Beckman Instruments, Fullerton, CA) during intravenous insulin infusion (primed 0.8 mU/kg continuous 1.2 mU/kg/min infusion of Novolin, Toronto, Mississauga, ON). This protocol was performed to control for any potential effect of the difference in plasma glucose level on postprandial fatty acid metabolism and tissue fatty acid oxidation (11). We previously demonstrated that subjects with type 2 diabetes display increased plasma palmitate and NEFA appearance and oxidation rates during steady-state postprandial condition without or with the glucose clamp using this insulin infusion protocol (10).

**PET/CT acquisitions.** The participants were positioned supine in a positron emission tomography coupled with computed tomography (PET/CT) scanner (Philips Gemini GXL; Philips, Eindhoven, the Netherlands) using a row action maximum likelihood algorithm (RAMLA) without sinogram rebinning for reconstructing images. The other parameters were as follows: isotropic voxel size of 4 mm, 60-cm diameter by 18-cm axial field of view. A CT scan (16 mA) of thighs was performed to correct for attenuation and for definition of PET regions of interests. At time 270 min after the beginning of continuous oral intake of the liquid meal, ~185 MBq of [11C]acetate, produced as previously described (12), was injected intravenously over 30 s followed by dynamic list-mode acquisition for 30 min (12 × 10, 8 × 30, 4 × 300, and 1 × 240 s) to quantitatively assess systemic NEFA blood flow and oxidative metabolism (13). Three participants (one CON and two type 2 diabetic subjects) did not receive the [11C]acetate because of delayed synthesis time of the tracer. 14(R,S)-[18F]fluoro-6-thia-heptadecanoic acid ([18F]THA), a long-chain fatty acid analog that produces as previously described (14). Approximately 180 MBq of this tracer in 5 mL 25% human albumin was administered intravenously over 30 s at time 330 min after the beginning of continuous meal intake followed by dynamic list-mode acquisition for 30 min (12 × 10, 8 × 30, and 8 × 180 s) to quantitatively assess plasma NEFA uptake of thigh tissues, as previously performed by others during the fasting state (15). Total radioactivity exposure to the participants was ~<80 MBq and nonionizing. The use in humans was approved by Health Canada and the Human Ethics Committee of the Centre Hospitalier Université de Sherbrooke.

The protocols started with 30 min bed rest, after which blood samples were taken at 10-min intervals at baseline (time = 0 to 10 min) and during the [18F]THA dynamic imaging protocols (time 330–360 min after the beginning of continuous meal intake) (Fig. 1). Blood was collected in tubes containing Na2EDTA and Orlistat (30 µg/mL; Roche, Mississauga, Canada) to prevent in vitro TG lipolysis (16).

**Radioisotopic assays.** Glucose, insulin, total NEFA, and TGs were measured as described (9). Fractional plasma [18F]THA and metabolites were determined by thin-layer chromatography, as previously described (17).

**PET/CT images analysis.** All image-derived input functions and the full-width at half-maximum were drawn on both the left and right femoral arteries over three consecutive planes, with an interval of 4 cm between planes. Corrections were applied on input function for partial volume and tissue-to-artery spill-in of radioactivity as described previously (18). The maximum value of the four highest adjacent pixels (stable uptake) of each tracer was recorded. Regions of interest were drawn on the skeletal muscle (quadriceps femoris [QF] and biceps femoris [BF], e.g., predominantly white and red muscle fibers, respectively) and subcutaneous fat of the femoral region to generate tissue time-radioactivity curves (Supplementary Fig. 1B), as recently performed by others to determine adipose tissue NEFA uptake during fasting (19). The regions of interest were first defined from the transaxial CT slices and then copied to both the [11C]acetate and [18F]THA image sequences. Large adipose regions were combined in the [11C]acetate and [18F]THA time-radioactivity curves, with a lumped input function (Supplementary Fig. 1C), as recently described (20). The rapid fractional tissue clearance (K) of [18F]THA was calculated as occurring in resting skeletal muscles, fast-tissue fractional extraction (K1), in min−1, of [11C]acetate and oxidative metabolism index (the rapid fractional tissue clearance, K1, in min−1, of [18F]THA) were estimated from [11C]acetate using a three-compartment model (13,20,21), as previously published by our group (18). At relatively low tissue blood flow rate as occurring in resting skeletal muscles, first-pass tissue fractional extraction of arterial [11C]acetate is close to 1 and provides a reliable index of tissue perfusion (22). Determination of tissue oxidative metabolism using the [11C]acetate method is based on the following assumptions: (13) 1 [11C]acetate enters the Krebs cycle freely after rapid conversion into acetyl-CoA; 2) other acetate metabolic pathways (e.g., de novo lipogenesis, amino acid transcarboxylation) are relatively slow compared with the Krebs cycle carbon fluxes; 3) carbon flux through the Krebs cycle and the production of reducing equivalents is stable and accounts for approximately two-thirds of total production; and 5) the production of reducing equivalents is tightly coupled with oxygen consumption.

The nonmetabolized fraction of [18F]THA was used to correct the plasma input function (Supplementary Fig. 1A) and plasma and femoral tissue time-radioactivity curves were analyzed graphically using the Patlak linearization method (Supplementary Fig. 1C) (17,18). The slope of the plot in the graphical analysis is equal to the tissue NEFA fractional extraction constant of [18F]THA (K). K1 was corrected for tissue density by multiplying the constant by the appropriate density (skeletal muscle: 1.0597 g/mL; adipose tissue: 0.9196 g/mL; Roche, Mississauga, Canada) to prevent in vitro TG lipolysis (16).

**Statistical analysis.** Data are expressed as mean ± SEM. Unpaired Student t test was used to compare differences in plasma insulin, NEFA, and TGs throughout the protocol. Spearman correlation coefficients were used to determine correlation between variables. A two-tailed P value of <0.05 was considered significant. All analyses were performed with the SAS software for Windows, version 9.1.3 (SAS Institute, Cary, NC) or GraphPad Prism version 5.00 for Windows (San Diego, CA).

**RESULTS**

**Participant characteristics and plasma metabolites and insulin levels.** Type 2 diabetic subjects were older and tended to have higher body fat than CON. Type 2 diabetic subjects also had significantly higher fasting plasma

**TABLE 1** Characteristics of the participants

|          | CON       | Type 2 diabetes |
|----------|-----------|-----------------|
| n        | 7         | 7               |
| Age (years) | 35 ± 5    | 50 ± 5          |
| BMI (kg/m²) | 27.6 ± 1.2 | 30.1 ± 2.3      |
| Weight (kg) | 86.2 ± 3.2 | 93.5 ± 9.3      |
| Lean weight (kg) | 65.8 ± 3.0 | 62.5 ± 4.4      |
| Nonlean weight (kg) | 20.8 ± 2.8 | 31.0 ± 5.3      |
| Fat percent (%) | 23.9 ± 2.8 | 32.1 ± 2.4      |
| Fasting glucose (mmol/L) | 5.1 ± 0.1 | 6.5 ± 0.3        |
| Fasting insulin (pmol/L) | 65 ± 16 | 140 ± 37         |
| Fasting NEFA (µmol/L) | 278 ± 34 | 370 ± 46         |
| Fasting TG (mmol/L) | 1.05 ± 0.21 | 1.35 ± 0.42    |
| Fasting cholesterol (mmol/L) | 4.30 ± 0.34 | 4.79 ± 0.23 |
| Fasting HDL cholesterol (mmol/L) | 1.40 ± 0.21 | 1.14 ± 0.13 |
| Fasting LDL cholesterol (mmol/L) | 2.30 ± 0.38 | 3.18 ± 0.19 |

Data are means ± SEM. *From the unpaired Student t test.
glucose levels and tended to have increased fasting plasma insulin, NEFA, and LDL cholesterol levels.

Plasma glucose was higher in type 2 diabetic subjects than in CON throughout the metabolic study (Fig. 2A) (ANOVA $P < 0.01$) with significant group $\times$ time interaction due to the clamp procedure in the last 3 h that abolished difference between the two groups during the PET/CT acquisition period (ANOVA $P = 0.45$). Plasma insulin, NEFA, and TGs (Fig. 2B, C, and D, respectively) were also significantly higher in type 2 diabetic subjects than in CON (all ANOVA $P < 0.01$) without significant group $\times$ time interaction.

Skeletal muscle blood flow and oxidative metabolic indexes. QF (predominantly white fibers) and BF (predominantly red fibers) blood flow indexes (Fig. 3A and B) tended to be lower in type 2 diabetic subjects than in CON (QF: $0.21 \pm 0.07$ vs. $0.32 \pm 0.04$ min, $P = 0.17$; BF: $0.22 \pm 0.05$ vs. $0.33 \pm 0.05$ min, $P = 0.17$). There was no significant difference in blood flow index between QF and BF in both groups of participants. Skeletal muscle oxidative metabolism indexes (Fig. 3C and D) were similar in type 2 diabetic subjects and CON (QF: $0.27 \pm 0.11$ vs. $0.44 \pm 0.24$ min, $P = 0.93$; BF: $0.15 \pm 0.09$ vs. $0.20 \pm 0.08$ min, $P = 0.66$).

Thigh skeletal muscle and subcutaneous adipose tissue NEFA fractional extraction and net NEFA uptake. NEFA fractional extraction in thigh skeletal muscles (Fig. 4A and B) was significantly decreased (by $\sim$56%) in type 2 diabetic subjects versus CON (QF: $0.019 \pm 0.003$ vs. $0.040 \pm 0.008$ min, $P = 0.03$; BF: $0.019 \pm 0.003$ vs. $0.045 \pm 0.011$ min, $P = 0.04$) and tended to be decreased.
FIG. 3. Skeletal muscle blood flow index (A and B) and oxidative metabolism index (C and D) in QF and BF, respectively, in the type 2 diabetic participants (T2D) (■) and CON (□). Data are means ± SEM.

(by ~47%) in subcutaneous fat in type 2 diabetic subjects versus CON (Fig. 4C; 0.010 ± 0.002 vs. 0.018 ± 0.004 min, \( P = 0.07 \)). However, NEFA uptake in thigh skeletal muscles (Fig. 4D and E) was similar in type 2 diabetic subjects and CON (QF: 1.47 ± 0.23 vs. 1.37 ± 0.24 nmol \( \cdot \) g\(^{-1} \) \cdot min\(^{-1} \), \( P = 0.77 \); BF: 1.54 ± 0.26 vs. 1.46 ± 0.28 nmol \( \cdot \) g\(^{-1} \) \cdot min\(^{-1} \), \( P = 0.85 \)). NEFA uptake in subcutaneous adipose tissue was also similar in type 2 diabetic subjects versus CON (Fig. 4F; 0.67 ± 0.15 vs. 0.52 ± 0.10 nmol \( \cdot \) g\(^{-1} \) \cdot min\(^{-1} \), \( P = 0.47 \)). NEFA fractional extraction in leg subcutaneous fat was negatively correlated with BMI (Fig. 5A; \( r = -0.69, P < 0.01 \)), but not with nonlean mass (\( r = -0.30, P = 0.30 \)) or % fat mass (\( r = -0.34, P = 0.23 \)). NEFA fractional extraction in skeletal muscles was positively correlated with muscle blood flow index (Fig. 5B and C; QF: \( r = 0.70, P = 0.02 \); BF: \( r = 0.71, P = 0.02 \)). We found a significant correlation between muscle blood flow index and NEFA fractional extraction in healthy subjects but not in subjects with type 2 diabetes in both muscles (QF: \( r = 0.88, P = 0.02 \), and \( r = 0.33, P = 0.50 \), in CON and type 2 diabetic subjects, respectively; BF: \( r = 0.99, P < 0.001 \), and \( r = 0.27, P = 0.66 \), in CON and type 2 diabetic subjects, respectively). There was no significant difference in NEFA fractional extraction and NEFA uptake between QF and BF in both groups of participants. We found no significant relationship between muscle blood flow index and net muscle NEFA uptake (QF: \( r = -0.14, P = 0.71 \); BF: \( r = 0.54, P = 0.11 \)) or between muscle NEFA fractional extraction and plasma NEFA level or muscle NEFA delivery (NEFA \( \times \) muscle NEFA blood flow index) (not shown).

DISCUSSION

The current study demonstrated that postprandial NEFA uptake in femoral skeletal muscle and subcutaneous adipose tissue is similar in type 2 diabetic subjects compared with healthy subjects despite increased circulating NEFA levels in the former. The rate of total muscle NEFA uptake reported herein using \( ^{18} \)FTHA PET/CT scanning in healthy men is compatible with the range of oxidative and nonoxidative muscle NEFA uptake reported during fasting by other groups using stable isotopic tracers and muscle biopsies or arterio-venous gradient (23,24). However, direct comparison between our technique and the later is difficult, since the current study reports total muscle NEFA uptake during the postprandial state. Remarkably, there was reduced muscle NEFA fractional extraction in type 2 diabetes that was directly related to reduction in muscle blood flow index during the postprandial state.

This result was observed despite acute correction of postprandial hyperglycemia in type 2 diabetes using the insulin clamp. The present results suggest that the circulating NEFA pool is an unlikely source for the excess postprandial IMTG deposition observed in type 2 diabetes (4). Our results lend indirect support for an important role of excessive uptake of dietary TG in muscle in type 2 diabetes, as we recently demonstrated in the myocardium of diabetic rats (17).

Lipotoxicity refers to the process leading to end-organ damage and/or dysfunction after excess exposure to fatty acids and was first coined in the context of fat-induced insulin resistance and impaired glucose-stimulated insulin secretion leading to type 2 diabetes. Increased postprandial NEFA appearance rate is one of the mechanisms that may potentially lead to increased non-adipose tissue NEFA uptake and fatty acid exposure in type 2 diabetic subjects (25–29). In the current study, we found no increase in net skeletal muscle NEFA uptake despite the expected increase in circulating NEFA levels during the
postprandial state in type 2 diabetes, a phenomenon attributable to significantly reduced muscle NEFA fractional extraction. The results of the current study apply only to fully established type 2 diabetes, and we cannot exclude that muscle plasma NEFA uptake plays a role in muscle TG accretion and lipotoxicity earlier in the natural history of type 2 diabetes. Turpeinen et al. (15) showed, also using the $^{18}$FTHA PET method, that glucose-intolerant subjects display decreased skeletal muscle NEFA uptake during fasting. In the later study, this was attributable to significant reduction in muscle NEFA fractional extraction with similar NEFA levels in subjects with impaired glucose tolerance. Kelley and Simoneau (28), using arterio-venous balance across the leg, found significant reduction of $[^3]$H oleate fractional extraction associated with reduced fat oxidation, as assessed by limb indirect calorimetry, at fasting and after intake of a mixed meal in type 2 diabetes. Because circulating NEFA levels were higher, these authors found that net NEFA uptake was nevertheless higher across the leg in type 2 diabetes. These differences between type 2 diabetic subjects and control subjects in leg NEFA uptake and oxidation tended to be reduced toward the end of the 6-h postprandial period. Plasma glucose levels were very high (between 10 and 13 mmol/L) at fasting and during the postprandial period in type 2 diabetes in the latter study, associated with increased leg glucose oxidation that may lead to reciprocal reduction in fatty acid oxidation (30). Finally, it should be noted that results from limb arterio-venous balance studies may also be influenced by tissues other than skeletal muscles.

We found a direct relationship between blood flow index and skeletal muscle NEFA fractional extraction in the current study, a relationship that was more apparent in healthy individuals than in subjects with type 2 diabetes. Insulin-resistant states are associated with reduced postprandial muscle blood flow (31), perhaps because of

**FIG. 4.** NEFA fractional extraction (A, B, and C) and net NEFA uptake (D, E, and F) in QF, BF, and subcutaneous fat, respectively, in the type 2 diabetic (T2D) participants (■) and CON (□). Data are means ± SEM. *$p < 0.05$ by unpaired Student $t$ test.
impaired insulin-mediated capillary recruitment (32,33). It was shown in some (32,33), but not other studies (34,35), that muscle blood flow may be rate limiting for muscle glucose uptake, at least at higher levels of insulin sensitivity. We found no significant relationship between muscle blood flow index and net muscle NEFA uptake or between muscle NEFA fractional extraction and plasma NEFA level or muscle NEFA, demonstrating no apparent saturation of muscle NEFA transport capacity in the present experimental conditions. However, it is not possible to establish a causal relationship between reduced muscle blood flow index and reduction in muscle NEFA fractional extraction in subjects with type 2 diabetes, since other sources of fatty acids such as excess circulating TGs may compete for muscle intracellular NEFA transport, leading to apparent reduction of NEFA fractional extraction.

[^18]FTHA has been used previously to determine abdominal adipose tissue NEFA uptake in men during fasting (19). In contrast to the clear reduction of chylomicron-derived fatty acid uptake in subcutaneous adipose tissues of insulin-resistant and type 2 diabetic individuals (25–27,29), we found that postprandial adipose tissue uptake of plasma NEFA was virtually identical in type 2 diabetic subjects and CON. However, we found that type 2 diabetic participants tended to have lower subcutaneous adipose tissue NEFA fractional extraction than CON. However, adipose tissue NEFA fractional extraction was inversely associated with BMI in the current study, a phenomenon perhaps attributable to reduced postprandial adipose tissue blood flow with obesity. In obese and/or insulin-resistant individuals, fasting as well as postprandial increase in subcutaneous adipose tissue blood flow is lower than in healthy normal-weight subjects (36–41). Reduction of postprandial adipose tissue blood flow correlates with impaired insulin sensitivity throughout the natural history of type 2 diabetes (42). Impaired postprandial adipose tissue blood flow has been related, at least in part, to impaired adipose tissue uptake of chylomicron-derived fatty acids in morbid obesity (43). Unfortunately, we could not assess adipose tissue blood flow index in the current study given the very low uptake of [11C]acetate in this tissue.

We could not find significant reduction of muscle oxidative metabolism in type 2 diabetes. This result contrasts with the results of others who found reduced skeletal muscle oxidative phosphorylation in prediabetic insulin-resistant individuals (44–46). The presence of impaired skeletal muscle mitochondrial oxidative capacity in type 2 diabetes is controversial (47,48). In subjects with type 2 diabetes, whole-body postprandial NEFA oxidation is increased, not reduced, whether glucose level is acutely corrected or not with insulin clamp (10). It should be noted that the [13C]acetate method we used is based on measurement of 13CO2 production from the [13C]acetyl-CoA intracellular pool (e.g., it is a measure of the Krebs cycle) (13). Mitochondrial uncoupling in vivo in skeletal muscle in type 2 diabetes could perhaps explain normal or high Krebs cycle carbon flux with reduced ATP production. Because our sample size was small, we cannot exclude that the lack of difference between type 2 diabetic subjects and CON in muscle oxidative metabolism in the current study could be due to a type 2 error.

The steady-state design of our postprandial study did not fully reproduce physiological meal intake and may lead to lower late postprandial overshoot of plasma NEFA level (49). This may have attenuated differences in skeletal muscle NEFA uptake between type 2 diabetes and CON in the current study. On the other hand, acute correction of postprandial hyperglycemia in type 2 diabetes is expected to increase fatty acid oxidation at the expense of glucose oxidation (11), leading to increased muscle fatty acid use in the latter. We used an identical postprandial protocol in a recent study without and with acute correction of hyperglycemia with insulin infusion and found nevertheless that type 2 diabetic subjects had higher whole-body postprandial plasma NEFA oxidation than CON in both conditions. Another limitation of our study is that [18]FTHA, a reliable tracer of net tissue NEFA uptake (14,15,50),
cannot distinguish oxidative versus nonoxidative tissue NEFA metabolism. We previously found elevated whole-body NEFA and net fatty acid oxidation during the postprandial state in type 2 diabetes (10). It is therefore possible that increased postprandial plasma NEFA oxidation in type 2 diabetes is the result of increased uptake and oxidation in other lean organs such as the heart and the liver.

In conclusion, similar postprandial skeletal muscle NEFA uptake in type 2 diabetic and control subjects in this study provides evidence against a major role for increased plasma NEFA in the postprandial fat accretion observed in muscles in type 2 diabetes. Impaired skeletal muscle blood flow leading to impaired muscle NEFA fractional extraction may explain this finding. The results of the current study suggest that other sources of excess fatty acid uptake such as circulating lipoprotein-TG may be responsible for acute postprandial IMTG accumulation in type 2 diabetes.

ACKNOWLEDGMENTS

This work was supported by a grant from the Canadian Institutes of Health Research (CIHR-MOP 539094) and was performed at the Centre de recherche clinique Étienne-Le Bel, a research center funded by the Fonds de la recherche en santé du Québec (FRSQ). A.C.C. is currently the recipient of a Fonds de recherche en santé du Québec Senior Scholarship Award. S.M.L. is the recipient of a Canadian Diabetes Association Doctoral Studentship Award.

No potential conflicts of interest relevant to this article were reported.

REFERENCES

1. Jacob S, Machann J, Rett K, et al. Association of increased intramyocellular lipid content with insulin resistance in lean nondiabetic offspring of diabetic subjects. Diabetes 1999;48:1113–1119
2. Boden G, Lebed B, Schatz M, Homko C, Lemieux S. Effects of acute changes of plasma free fatty acids on intramyocellular fat content and insulin resistance in healthy subjects. Diabetes 2001;50:1612–1617
3. Bachmann OP, Dahl DB, Brechtel K, et al. Effects of intravenous and dietary lipid challenge on intramyocellular lipid content and the relation with insulin sensitivity in humans. Diabetes 2001;50:2579–2584
4. Ravikumar B, Carey PE, Snaar JE, et al. Real-time assessment of postprandial fat storage in liver and skeletal muscle in health and type 2 diabetes. Am J Physiol Endocrinol Metab 2005;289:E849–E857
5. Kelley DE, Goodpaster B, Wing RR, Simoneau JA. Skeletal muscle fatty acid metabolism in association with insulin resistance, obesity, and weight loss. Am J Physiol 1999;277:E130–E1141
6. Blaak EE, Wagenmakers AJ. The fate of [U-13C]palmitate extracted by skeletal muscle in subjects with type 2 diabetes and control subjects. Diabetes 2002;51:784–789
7. Halvorsen OE, Berggren JR, Cortright RN, et al. Skeletal muscle lipid metabolism with obesity. Am J Physiol Endocrinol Metab 2003;284:E741–E747
8. Carpenter AC, Bourbonnais A, Frisch F, Giacca A, Lewis GF. Plasma nonesterified fatty acid intolerance and hyperglycemia are associated with intravenous lipid-induced impairment of insulin sensitivity and disposition index. J Clin Endocrinol Metab 2010;95:1256–1261
9. Brerat P, Frisch F, Lavoie F, et al. Impaired plasma nonesterified fatty acid oxidation is an early defect in the natural history of type 2 diabetes. J Clin Endocrinol Metab 2008;93:837–844
10. Norman-Lauzière F, Frisch F, Labbé SM, et al. Increased postprandial nonesterified fatty acid appearance and oxidation in type 2 diabetes is not fully established in offspring of diabetic subjects. PLoS ONE 2010;5:e10956
11. Sidossis LS, Stuart CA, Shulman GI, Lopaschuk GD, Wolfe RR. Glucose plus insulin regulate fat oxidation by controlling the rate of fatty acid entry into the mitochondria. J Clin Invest 1996;98:2244–2250
12. Ménard SL, Ci X, Frisch F, et al. Mechanism of reduced myocardial glucose utilization during acute hyperglycemia in rats. Mol Imaging Biol 2009;11:6–14
13. Klein LJ, Visser FC, Knaapen P, et al. Carbon-11 acetate as a tracer of myocardial oxygen consumption. Eur J Nucl Med 2001;28:651–668
14. Ci X, Frisch F, Lavoie F, et al. The effect of insulin on the intracellular distribution of 14(R,S)-[18F]fluoro-6-thia-htadeptcapionic acid in rats. Mol Imaging Biol 2006;8:237–244
15. Turpeinen AK, Takala TO, Nauttia P, et al. Impaired free fatty acid uptake in skeletal muscle but not in myocardium in patients with impaired glucose tolerance: studies with PET and 14(R,S)-[18F]fluoro-6-thia-htadeptcapionic acid. Diabetes 1999;48:1245–1250
16. Carpentier AC, Frisch F, Cyr D, et al. On the suppression of plasma nonesterified fatty acids by insulin during enhanced intravascular lipolysis in humans. Am J Physiol Endocrinol Metab 2005;289:E480–E486
17. Ménard SL, Croteau E, Sarrhini O, et al. Abnormal in vivo myocardial energy substrate uptake in diet-induced type 2 diabetic cardiomyopathy in rats. Am J Physiol Endocrinol Metab 2010;298:E1048–E1057
18. Croteau E, Lavalée E, Labbé SM, et al. Image-derived input function in dynamic PET/CT methodology and validation with [11C-acetate and 18F-fluorothioheptadecanoic acid in muscle and 18F-fluorodeoxyglucose in brain. Eur J Nucl Med Mol Imaging 2010;37:1359–1360
19. Hannukainen JC, Kallikoski KK, Borra RJ, et al. Higher free fatty acid uptake in visceral than in abdominal subcutaneous fat tissue in men. Obesity (Silver Spring) 2010;18:261–265
20. Brown M, Marshall DR, Sobel BE, Bergmann SR. Delineation of myocardial oxygen utilization with carbon-11-labeled acetate. Circulation 1987;76:687–696
21. Armbrecht JJ, Buxton DB, Brunken RC, Phelps ME, Schelbert HR. Regional myocardial oxygen consumption determined noninvasively in humans with [1-13C]-acetate and dynamic positron tomography. Circulation 1989;80:863–872
22. van den Hoff J, Burecht W, Borner AR, et al. [1-(11)C]acetate as a quantitative perfusion tracer in myocardial PET. J Nucl Med 2001;42:1174–1182
23. Kanaley JA, Shadid S, Sheehan MT, Guo Z, Jensen MD. Relationship between plasma free fatty acid, intramyocellular triglycerides and long-chain acylcarnitines in resting humans. J Physiol 2009;587:5089–5096
24. Helge JW, Stålhammar B, Roverso E, Galbo H, Kjær K. Muscle metabolism during graded quadriceps exercise in man. J Physiol 2007;581:1247–1258
25. Frayn KN, Humphreys SM, Coppack SW. Net carbon flux across subcutaneous adipose tissue after a standard meal in normal-weight and insulin-resistant obese subjects. Int J Obes Relat Metab Disord 1998;20:795–800
26. Roust LR, Jensen MD. Postprandial free fatty acid kinetics are abnormal in upper body obesity. Diabetes 1993;42:1567–1573
27. Guo ZK, Hensrud DD, Johnson CM, Jensen MD. Regional postprandial fatty acid metabolism in different obesity phenotypes. Diabetes 1999;48:1356–1362
28. Kelley DE, Simoneau JA. Impaired free fatty acid utilization by skeletal muscle in non-insulin-dependent diabetes mellitus. J Clin Invest 1994;94:2349–2356
29. Miles JM, Wooldridge D, Grelle WJ, et al. Nocturnal and postprandial free fatty acid kinetics in normal and type 2 diabetic subjects: effects of insulin sensitization therapy. Diabetes 2003;52:675–681
30. Sidossis LS, Mitterndorfer B, Walse K, Chinkes D, Wolfe RR. Hyperglycemia-induced inhibition of splanchic fatty acid oxidation increases hepatic triacylglycerol secretion. J Physiol 1998;516:465–481
31. Skilton MR, Lai NT, Griffiths RA, et al. Meal-related increases in vascular reactive hyperemia are impaired in older and diabetic adults: insights into roles of aging and insulin in vascular flow. Am J Physiol Heart Circ Physiol 2005;288:H1404–H1410
32. Holmaa A, Müller M, Andersson OK, Laine H, et al. Regional blood flow in skeletal muscle. Am J Physiol 1998;274:E446–E452
33. Baran AD, Tarshoby M, Hook G, et al. Interaction between insulin sensitivity and muscle perfusion on glucose uptake in human skeletal muscle: evidence for capillary recruitment. Diabetes 2000;49:768–774
34. Vollenweider I, Tappy L, Oyuela R, Jéquier E, Nicod P, Scherrer U. Insulin-induced sympathic activation and vasodilation in skeletal muscle: effects of insulin resistance in lean subjects. Diabetes 1995;44:641–645
35. Nauttia P, Raitakari M, Laine H, et al. Role of blood flow in regulating insulin-stimulated glucose uptake in humans: studies using bradykinin, [18F]water, and [18F]deoxy-glucose and positron emission tomography. J Clin Invest 1996;97:1741–1747
36. Coppack SW, Evans RD, Fisher RM, et al. Adipose tissue metabolism in obesity: lipase action in vivo before and after a mixed meal. Metabolism 1992;41:264–272
37. Blaak EE, van Baak MA, Kemerink GJ, Pakhiers MT, Heidendal GA, Saris WH. Beta-adrenergic stimulation and abdominal subcutaneous fat blood flow in lean, obese, and reduced-obese subjects. Metabolism 1995;44:183–187
38. Summers LK, Samra JS, Humphreys SM, Morris RJ, Frayn KN. Subcutaneous abdominal adipose tissue blood flow: variation within and between subjects and relationship to obesity. Clin Sci (Lond) 1996;91:670–683
39. Jansson PA, Larsson A, Lonnroth PN. Relationship between blood pressure, metabolic variables and blood flow in obese subjects with or without non-insulin-dependent diabetes mellitus. Eur J Clin Invest 1998;28:813–818
40. Karpe F, Fielding BA, Ilic V, Macdonald IA, Summers LK, Frayn KN. Impaired postprandial adipose tissue blood flow response is related to aspects of insulin sensitivity. Diabetes 2002;51:2467–2473
41. Virtanen KA, Peltoniemi P, Marjamaki P, et al. Human adipose tissue glucose uptake determined using [(18)F]-fluoro-deoxy-glucose ([(18)F]FDG) and PET in combination with microdialysis. Diabetologia 2001;44:2171–2179
42. Dimitriadis G, Lambadiari V, Mitrou P, et al. Impaired postprandial blood flow in adipose tissue may be an early marker of insulin resistance in type 2 diabetes. Diabetes Care 2007;30:3128–3130
43. Mitrou P, Boutati E, Lambadiari V, et al. Rates of lipid fluxes in adipose tissue in vivo after a mixed meal in morbid obesity. Int J Obes (Lond) 2010;34:770–774
44. Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 2004;350:664–671
45. Befroy DE, Petersen KF, Dufour S, et al. Impaired mitochondrial substrate oxidation in muscle of insulin-resistant offspring of type 2 diabetic patients. Diabetes 2007;56:1376–1381
46. Heilbronn LK, Gregersen S, Shirkhedkar D, Hu D, Campbell LV. Impaired fat oxidation after a single high-fat meal in insulin-sensitive nondiabetic individuals with a family history of type 2 diabetes. Diabetes 2007;56:2046–2053
47. Boushel R, Gnaiger E, Schjerling P, Skovbro M, Kraunsæ R, Dela F. Patients with type 2 diabetes have normal mitochondrial function in skeletal muscle. Diabetologia 2007;50:790–796
48. Lenaers E, De Feyter HM, Hoeks J, et al. Adaptations in mitochondrial function parallel, but fail to rescue, the transition to severe hyperglycemia and hyperinsulinemia: a study in Zucker diabetic fatty rats. Obesity (Silver Spring) 2010;18:1100–1107
49. Barrows BR, Timlin MT, Parks EJ. Spillover of dietary fatty acids and use of serum nonesterified fatty acids for the synthesis of VLDL-triacylglycerol under two different feeding regimens. Diabetes 2005;54:2668–2673
50. Knuuti J, Takala TO, Någren K, et al. Myocardial fatty acid oxidation in patients with impaired glucose tolerance. Diabetologia 2001;44:184–187